{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:12:42Z","timestamp":1791198762054,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.01.024","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T12:30:30Z","timestamp":1490013030000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer"],"prefix":"10.1016","volume":"76","author":[{"given":"Christophe","family":"Massard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Nguyen","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pascal","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Turri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-9380","authenticated-orcid":false,"given":"Joan","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denes","family":"Csonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunava","family":"Chakravartty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.01.024_bib1","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.01.024_bib2","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-10-2815","article-title":"Targeting continued androgen receptor signaling in prostate cancer","volume":"17","author":"Massard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.01.024_bib3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.bjc.6605554","article-title":"Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer","volume":"102","author":"Reid","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.01.024_bib4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2011.117","article-title":"The changing therapeutic landscape of castration-resistant prostate cancer","volume":"8","author":"Yap","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.024_bib5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/sj.bjc.6604904","article-title":"CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer","volume":"100","author":"Ang","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.01.024_bib6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.01.024_bib7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2017.01.024_bib8","doi-asserted-by":"publisher","first-page":"7929","DOI":"10.1158\/0008-5472.CAN-06-1637","article-title":"Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice","volume":"66","author":"Gao","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.01.024_bib9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.01.024_bib10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.024_bib11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.3005","article-title":"First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients with advanced solid tumors","volume":"28","author":"Burris","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.024_bib12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.01.024_bib13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.01.024_bib14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.01.024_bib15","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","article-title":"Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel","volume":"50","author":"Fitzpatrick","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.01.024_bib16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/annonc\/mds624","article-title":"Prostate cancer: ESMO consensus conference guidelines 2012","volume":"24","author":"Horwich","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.01.024_bib17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.juro.2009.06.025","article-title":"Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy","volume":"182","author":"Ham","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2017.01.024_bib18","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-08-0125","article-title":"Targeting the PI3K\/AKT pathway for the treatment of prostate cancer","volume":"15","author":"Sarker","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.01.024_bib19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2013.03.040","article-title":"Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08\/08)","volume":"64","author":"Templeton","year":"2013","journal-title":"Eur Urol"},{"issue":"Suppl. 6","key":"10.1016\/j.ejca.2017.01.024_bib20","doi-asserted-by":"crossref","first-page":"vi243","DOI":"10.1093\/annonc\/mdw372.02","article-title":"PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"27","author":"de Bono","year":"2016","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2017.05.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T04:18:17Z","timestamp":1601785097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917300850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":20,"alternative-id":["S0959804917300850"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.024","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2017.05.003","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}